Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.Cancers|December 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD StudyEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.Journal of Cellular Physiology|December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experienceLaura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.European Journal of Cancer (Oxford, England : 1990)|April 1, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian studyRoberta Scafetta, Raffaella Troiano, Carla Gullotta, et al.Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.Pageof 6